Mechanisms of Neovascularization and Resistance to Anti-angiogenic Therapies in Glioblastoma Multiforme

Overview

Journal J Mol Med (Berl)

Specialty General Medicine

Date 2013 Mar 21

PMID 23512266

Citations 81

Authors

Yasushi Soda

Chad Myskiw

Amy Rommel

Inder M Verma

Affiliations

Soon will be listed here.

Abstract

Glioblastoma multiforme (GBM) is the most malignant brain tumor and highly resistant to intensive combination therapies. GBM is one of the most vascularized tumors and vascular endothelial growth factor (VEGF) produced by tumor cells is a major factor regulating angiogenesis. Successful results of preclinical studies of anti-angiogenic therapies using xenograft mouse models of human GBM cell lines encouraged clinical studies of anti-angiogenic drugs, such as bevacizumab (Avastin), an anti-VEGF antibody. However, these clinical studies have shown that most patients become resistant to anti-VEGF therapy after an initial response. Recent studies have revealed some resistance mechanisms against anti-VEGF therapies involved in several types of cancer. In this review, we address mechanisms of angiogenesis, including unique features in GBMs, and resistance to anti-VEGF therapies frequently observed in GBM. Enhanced invasiveness is one such resistance mechanism and recent works report the contribution of activated MET signaling induced by inhibition of VEGF signaling. On the other hand, tumor cell-originated neovascularization including tumor-derived endothelial cell-induced angiogenesis and vasculogenic mimicry has been suggested to be involved in the resistance to anti-VEGF therapy. Therefore, these mechanisms should be targeted in addition to anti-angiogenic therapies to achieve better results for patients with GBM.

Citing Articles

Vascular mimicry in zebrafish fin regeneration: how macrophages build new blood vessels.

Senk A, Fazzari J, Djonov V Angiogenesis. 2024; 27(3):397-410.

PMID: 38546923 PMC: 11303510. DOI: 10.1007/s10456-024-09914-y.

Vasculogenic Mimicry Occurs at Low Levels in Primary and Recurrent Glioblastoma.

Maddison K, Faulkner S, Graves M, Fay M, Bowden N, Tooney P Cancers (Basel). 2023; 15(15).

PMID: 37568738 PMC: 10417556. DOI: 10.3390/cancers15153922.

Clinicopathological significance of vasculogenic mimicry and fetal hemoglobin expression in peripheral neuroblastic tumors in children.

Zhang A, Zhang S Am J Transl Res. 2023; 15(7):4687-4698.

PMID: 37560203 PMC: 10408510.

SNORD17-mediated KAT6B mRNA 2'-O-methylation regulates vasculogenic mimicry in glioblastoma cells.

Cui J, Liu X, Dong W, Liu Y, Ruan X, Zhang M Cell Biol Toxicol. 2023; 39(6):2841-2860.

PMID: 37058271 DOI: 10.1007/s10565-023-09805-w.

Pan-cancer analysis of the prognosis and immunological role of AKAP12: A potential biomarker for resistance to anti-VEGF inhibitors.

Liang Q, Peng J, Xu Z, Li Z, Jiang F, Ouyang L Front Genet. 2022; 13:943006.

PMID: 36110213 PMC: 9468827. DOI: 10.3389/fgene.2022.943006.

References

Kreisl T, Kim L, Moore K, Duic P, Royce C, Stroud I . Phase II trial of single-agent bevacizumab followed by bevacizumab plus irinotecan at tumor progression in recurrent glioblastoma. J Clin Oncol. 2008; 27(5):740-5. PMC: 2645088. DOI: 10.1200/JCO.2008.16.3055. View

Vredenburgh J, Desjardins A, Herndon 2nd J, Dowell J, Reardon D, Quinn J . Phase II trial of bevacizumab and irinotecan in recurrent malignant glioma. Clin Cancer Res. 2007; 13(4):1253-9. DOI: 10.1158/1078-0432.CCR-06-2309. View

Liu X, Zhang Q, Mu Y, Zhang X, Sai K, Pang J . Clinical significance of vasculogenic mimicry in human gliomas. J Neurooncol. 2011; 105(2):173-9. PMC: 3198193. DOI: 10.1007/s11060-011-0578-5. View

Vitolo D, Paradiso P, Uccini S, Ruco L, Baroni C . Expression of adhesion molecules and extracellular matrix proteins in glioblastomas: relation to angiogenesis and spread. Histopathology. 1996; 28(6):521-8. DOI: 10.1046/j.1365-2559.1996.d01-471.x. View

Narayana A, Gruber D, Kunnakkat S, Golfinos J, Parker E, Raza S . A clinical trial of bevacizumab, temozolomide, and radiation for newly diagnosed glioblastoma. J Neurosurg. 2011; 116(2):341-5. DOI: 10.3171/2011.9.JNS11656. View

Friedmann-Morvinski D, Bushong E, Ke E, Soda Y, Marumoto T, Singer O . Dedifferentiation of neurons and astrocytes by oncogenes can induce gliomas in mice. Science. 2012; 338(6110):1080-4. PMC: 3595315. DOI: 10.1126/science.1226929. View

Purhonen S, Palm J, Rossi D, Kaskenpaa N, Rajantie I, Yla-Herttuala S . Bone marrow-derived circulating endothelial precursors do not contribute to vascular endothelium and are not needed for tumor growth. Proc Natl Acad Sci U S A. 2008; 105(18):6620-5. PMC: 2365563. DOI: 10.1073/pnas.0710516105. View

Forsythe J, Jiang B, Iyer N, Agani F, Leung S, Koos R . Activation of vascular endothelial growth factor gene transcription by hypoxia-inducible factor 1. Mol Cell Biol. 1996; 16(9):4604-13. PMC: 231459. DOI: 10.1128/MCB.16.9.4604. View

Brat D, Castellano-Sanchez A, Hunter S, Pecot M, Cohen C, Hammond E . Pseudopalisades in glioblastoma are hypoxic, express extracellular matrix proteases, and are formed by an actively migrating cell population. Cancer Res. 2004; 64(3):920-7. DOI: 10.1158/0008-5472.can-03-2073. View

10.

Li J, Sainson R, Oon C, Turley H, Leek R, Sheldon H . DLL4-Notch signaling mediates tumor resistance to anti-VEGF therapy in vivo. Cancer Res. 2011; 71(18):6073-83. DOI: 10.1158/0008-5472.CAN-11-1704. View

11.

Schnell O, Krebs B, Wagner E, Romagna A, Beer A, Grau S . Expression of integrin alphavbeta3 in gliomas correlates with tumor grade and is not restricted to tumor vasculature. Brain Pathol. 2008; 18(3):378-86. PMC: 2607528. DOI: 10.1111/j.1750-3639.2008.00137.x. View

12.

Koshikawa N, Giannelli G, Cirulli V, Miyazaki K, Quaranta V . Role of cell surface metalloprotease MT1-MMP in epithelial cell migration over laminin-5. J Cell Biol. 2000; 148(3):615-24. PMC: 2174802. DOI: 10.1083/jcb.148.3.615. View

13.

Charles N, Ozawa T, Squatrito M, Bleau A, Brennan C, Hambardzumyan D . Perivascular nitric oxide activates notch signaling and promotes stem-like character in PDGF-induced glioma cells. Cell Stem Cell. 2010; 6(2):141-52. PMC: 3818090. DOI: 10.1016/j.stem.2010.01.001. View

14.

Neyns B, Sadones J, Chaskis C, Dujardin M, Everaert H, Lv S . Phase II study of sunitinib malate in patients with recurrent high-grade glioma. J Neurooncol. 2010; 103(3):491-501. DOI: 10.1007/s11060-010-0402-7. View

15.

Brooks P, Montgomery A, Rosenfeld M, Reisfeld R, Hu T, Klier G . Integrin alpha v beta 3 antagonists promote tumor regression by inducing apoptosis of angiogenic blood vessels. Cell. 1994; 79(7):1157-64. DOI: 10.1016/0092-8674(94)90007-8. View

16.

Jin Z, Ueba H, Tanimoto T, Lungu A, Frame M, Berk B . Ligand-independent activation of vascular endothelial growth factor receptor 2 by fluid shear stress regulates activation of endothelial nitric oxide synthase. Circ Res. 2003; 93(4):354-63. DOI: 10.1161/01.RES.0000089257.94002.96. View

17.

Wijelath E, Murray J, Rahman S, Patel Y, Ishida A, Strand K . Novel vascular endothelial growth factor binding domains of fibronectin enhance vascular endothelial growth factor biological activity. Circ Res. 2002; 91(1):25-31. DOI: 10.1161/01.res.0000026420.22406.79. View

18.

Reardon D, Vredenburgh J, Coan A, Desjardins A, Peters K, Gururangan S . Phase I study of sunitinib and irinotecan for patients with recurrent malignant glioma. J Neurooncol. 2011; 105(3):621-7. PMC: 3748953. DOI: 10.1007/s11060-011-0631-4. View

19.

Scully S, Francescone R, Faibish M, Bentley B, Taylor S, Oh D . Transdifferentiation of glioblastoma stem-like cells into mural cells drives vasculogenic mimicry in glioblastomas. J Neurosci. 2012; 32(37):12950-60. PMC: 3461581. DOI: 10.1523/JNEUROSCI.2017-12.2012. View

20.

Giannelli G, SCHIRALDI O, Stetler-Stevenson W, Quaranta V . Induction of cell migration by matrix metalloprotease-2 cleavage of laminin-5. Science. 1997; 277(5323):225-8. DOI: 10.1126/science.277.5323.225. View